295 related articles for article (PubMed ID: 32666647)
1. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
Satake H; Kato T; Oba K; Kotaka M; Kagawa Y; Yasui H; Nakamura M; Watanabe T; Matsumoto T; Kii T; Terazawa T; Makiyama A; Takano N; Yokota M; Okita Y; Matoba K; Hasegawa H; Tsuji A; Komatsu Y; Yoshino T; Yamazaki K; Mishima H; Oki E; Nagata N; Sakamoto J
Oncologist; 2020 Dec; 25(12):e1855-e1863. PubMed ID: 32666647
[TBL] [Abstract][Full Text] [Related]
2. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
3. Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer.
Ishizaki T; Mazaki J; Enomoto M; Shigoka M; Kasahara K; Matsudo T; Kawakita H; Nagakawa Y; Katsumata K; Tsuchida A
Anticancer Res; 2021 Apr; 41(4):2157-2163. PubMed ID: 33813427
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study.
Li RR; Zhou HJ; Zeng DY; Jiang SF; Liu W; Frühling P; Liu ZY
J Gastrointest Oncol; 2024 Apr; 15(2):612-629. PubMed ID: 38756644
[TBL] [Abstract][Full Text] [Related]
5. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y
ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811
[TBL] [Abstract][Full Text] [Related]
7. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.
Kuboki Y; Nishina T; Shinozaki E; Yamazaki K; Shitara K; Okamoto W; Kajiwara T; Matsumoto T; Tsushima T; Mochizuki N; Nomura S; Doi T; Sato A; Ohtsu A; Yoshino T
Lancet Oncol; 2017 Sep; 18(9):1172-1181. PubMed ID: 28760399
[TBL] [Abstract][Full Text] [Related]
8. [Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
Naito A; Iwamoto K; Ohtsuka M; Imasato M; Inui M; Zenitani S; Wada R; Nakahara Y; Mikamori M; Furukawa K; Moon J; Asaoka T; Kishi K; Akamatsu H
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2104-2106. PubMed ID: 33468875
[TBL] [Abstract][Full Text] [Related]
9. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
Martínez-Lago N; Chucla TC; De Castro BA; Ponte RV; Rendo CR; Rodriguez MIG; Diaz SS; Suarez BG; de la Cámara Gomez J; Fernández FB; Salvador MM; Lopez MR
Sci Rep; 2022 Aug; 12(1):14612. PubMed ID: 36028552
[TBL] [Abstract][Full Text] [Related]
11. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
12. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
Yoshida Y; Yamada T; Kamiyama H; Kosugi C; Ishibashi K; Yoshida H; Ishida H; Yamaguchi S; Kuramochi H; Fukazawa A; Sonoda H; Yoshimatsu K; Matsuda A; Hasegawa S; Sakamoto K; Otsuka T; Koda K;
Int J Clin Oncol; 2021 Jan; 26(1):111-117. PubMed ID: 33083913
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii H; Matsuhashi N; Kitahora M; Takahashi T; Hirose C; Iihara H; Yamada Y; Watanabe D; Ishihara T; Suzuki A; Yoshida K
Oncologist; 2020 Mar; 25(3):e469-e476. PubMed ID: 32162797
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy and Safety of Standard and Biweekly Trifluridine/Tipiracil Regimen in Patients With Colorectal Cancer.
Hara S; Sakai D; Ikemura K; Shintani T; Yamamoto T; Satoh T; Okuda M
Anticancer Res; 2024 Mar; 44(3):1219-1226. PubMed ID: 38423630
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer.
Cecchini M; Kortmansky JS; Cui C; Wei W; Thumar JR; Uboha NV; Hafez N; Lacy J; Fischbach NA; Sabbath KD; Gomez CM; Sporn JR; Stein S; Hochster HS
Cancer; 2021 May; 127(9):1417-1424. PubMed ID: 33351187
[TBL] [Abstract][Full Text] [Related]
16. Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer.
Yoshida Y; Sakamoto R; Kajitani R; Munechika T; Matsumoto Y; Komono A; Aisu N; Daibo K; Kiyomi F; Hasegawa S
Anticancer Res; 2018 Jul; 38(7):4367-4373. PubMed ID: 29970575
[TBL] [Abstract][Full Text] [Related]
17. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkers.
Takahashi M; Sakamoto Y; Ohori H; Tsuji Y; Kuroki M; Kato S; Otsuka K; Komine K; Takahashi M; Takahashi S; Shirota H; Ouchi K; Takahashi Y; Imai H; Shibata H; Yoshioka T; Tanaka M; Yamaguchi H; Yamaguchi T; Shimodaira H; Ishioka C
Cancer Chemother Pharmacol; 2021 Sep; 88(3):393-402. PubMed ID: 34028598
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
20. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Matsumoto T; Yamamoto Y; Kotaka M; Masuishi T; Tsuji Y; Shoji H; Hirata K; Tsuduki T; Makiyama A; Izawa N; Takahashi N; Tsuda M; Yasui H; Ohta T; Kito Y; Otsu S; Hironaka S; Yamazaki K; Boku N; Hyodo I; Yoshimura K; Muro K
Target Oncol; 2024 Mar; 19(2):181-190. PubMed ID: 38427280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
